Dixon S C, Zalles A, Giordano C, Lush R M, Venzon D, Reed E, Figg W D
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892, USA.
Cancer Lett. 1997 Feb 26;113(1-2):111-6. doi: 10.1016/s0304-3835(97)04603-x.
Secondary hormonal manipulations are common following the failure of combined androgen blockade in patients with metastatic prostate cancer. Ketoconazole has been shown to have activity in this disease by inhibiting cytochrome P450 steroid hormone biosynthesis, thus inducing androgen deprivation. Gallium nitrate has been reported to target tumor tissue in vitro and some preliminary data suggests activity in patients with prostate cancer. Thus, we conducted a Phase II study of gallium nitrate in patients with androgen-independent prostate cancer. Two patients with progressive prostate cancer were removed from this study and subsequently placed on ketoconazole, as a palliative agent. Surprisingly, both of these patients had a greater than 50% decline in their prostate specific antigen (PSA) with this secondary endocrine maneuver. Based on this clinical observation, we conducted the following in vitro study to determine if there was a substantial additive effect of gallium nitrate followed by ketoconazole. Gallium nitrate or ketoconazole was added to the androgen-independent prostatic epithelial cell line, PC-3. One hundred and twenty hours (120 h) following the addition of one of the agents, the media was aspirated and the second agent was added to the wells. One plate was assayed every 24 h for cell viability using a non-isotopic cell proliferation assay kit. Cells treated with gallium nitrate followed by ketoconazole were 70-100% of control at the end of the gallium nitrate treatment; ketoconazole was then added and viability either remained constant or dropped steadily. Gallium nitrate by itself had a weak inhibitory effect on cell viability that only became apparent at the highest concentration evaluated. Ketoconazole, on the other hand, showed a substantial growth inhibition that was concentration-dependent. Cells treated with this agent alone showed a pronounced steady decrease in viability. Exposure to ketoconazole for 120 h followed by incubation in culture medium alone for 120 h caused a decrease in cell viability to 26.0% of control. Our in vitro results suggest that the combination of gallium nitrate and ketoconazole has no additive activity in the PC-3 cell line. Furthermore, this study confirms that ketoconazole added to prostate cancer cells has antiproliferative activity. The in vitro activity of ketoconazole has traditionally been thought to result from its inhibition of cytochrome P450-dependent enzymes responsible for steroidogenesis; however, an alternative hypothesis is necessary to explain the cytotoxic effect in the absence of adrenal and testicular androgen production as found in an in vitro system.
对于转移性前列腺癌患者,在联合雄激素阻断治疗失败后,二次激素治疗很常见。酮康唑已被证明通过抑制细胞色素P450类固醇激素生物合成而对该疾病具有活性,从而诱导雄激素剥夺。据报道,硝酸镓在体外靶向肿瘤组织,一些初步数据表明其对前列腺癌患者有活性。因此,我们对硝酸镓在雄激素非依赖性前列腺癌患者中进行了一项II期研究。两名前列腺癌进展患者被排除在本研究之外,随后接受酮康唑作为姑息治疗药物。令人惊讶的是,这两名患者通过这种二次内分泌治疗,其前列腺特异性抗原(PSA)下降超过50%。基于这一临床观察,我们进行了以下体外研究,以确定硝酸镓联合酮康唑是否存在显著的相加作用。将硝酸镓或酮康唑添加到雄激素非依赖性前列腺上皮细胞系PC-3中。在添加其中一种药物120小时后,吸出培养基并向孔中添加第二种药物。使用非同位素细胞增殖检测试剂盒每24小时检测一组细胞的活力。先用硝酸镓处理然后用酮康唑处理的细胞在硝酸镓处理结束时为对照的70 - 100%;然后添加酮康唑,细胞活力要么保持不变,要么稳步下降。硝酸镓本身对细胞活力有微弱的抑制作用,只有在评估的最高浓度时才变得明显。另一方面,酮康唑显示出显著的生长抑制作用,且呈浓度依赖性。单独用该药物处理的细胞活力明显稳步下降。用酮康唑处理120小时,然后在单独的培养基中孵育120小时,导致细胞活力降至对照的26.0%。我们的体外研究结果表明,硝酸镓和酮康唑联合使用在PC-3细胞系中没有相加活性。此外,本研究证实,添加到前列腺癌细胞中的酮康唑具有抗增殖活性。传统上认为酮康唑的体外活性是由于其抑制负责类固醇生成的细胞色素P450依赖性酶;然而,在体外系统中,在没有肾上腺和睾丸雄激素产生的情况下,需要另一种假说来解释其细胞毒性作用。